ARCHIVES

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

This article is from The Cancer Letter archive.

Vol. 35 No. 5 | May 25, 2012

Download PDF Visit The Full Archive

Related Articles

Special Report: KRAS Finding Changes Oncology Practice But Poses Profound Regulatory Dilemma

January 30, 2009

NCCS Networker Volume 1 Issue 2, Summer 1987

June 13, 1987

Funding Opporunities: Program Announcments

January 15, 1999

Scientists, Industry Identify Barriers To Development of Molecular Therapies

April 12, 2002

Appropriators Ask What Happens After NIH Budget-Doubling Ends In FY2004.

May 25, 2001

Las Vegas Cancer Center Cuts Staff, Seeks Lifelines During “Perfect Storm”

May 20, 2011